Nationwide Seroprevalence of SARS-CoV-2 in Saudi Arabia

  1. Naif Khalaf Alharbi
  2. Suliman Alghnam
  3. Abdullah Algaissi
  4. Hind Albalawi
  5. Mohammed W. Alenazi
  6. Areeb M. Albargawi
  7. Abdullah G. Alharbi
  8. Abdulaziz Alhazmi
  9. Ali Al Qarni
  10. Ali Alfarhan
  11. Hosam M. Zowawi
  12. Hind Alhatmi
  13. Jahad Alghamdi
  14. Fayhan Alroqi
  15. Khalid Batarfi
  16. Yaseen M. Arabi
  17. Anwar M. Hashem
  18. Mohammed Bosaeed
  19. Omar Aldibasi

Reviewed by

Read the full article

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.jiph.2021.04.006
  2. ScreenIT

    SciScore for 10.1101/2021.01.28.21250598: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementConsent: COVID-19 patients and HCWs signed informed consents to give blood samples.
    RandomizationThen, we randomly selected five positive pools per population from all regions, except for Jazan D population, for individual testing to obtain the average number of positive individual samples per population per region.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Plates were washed, and 50 μl of 1:1000 diluted alkaline phosphatase labeled goat anti-human IgG secondary antibody (Thermo Fisher, Waltham, MA) were added and incubated for one hour at RT.
    anti-human IgG
    suggested: None
    Software and Algorithms
    SentencesResources
    All statistical analyses were conducted using SAS 9.4 (SAS Institute Inc., Cary, NC) and GraphPad Prism V8 software (GraphPad Co.). Ethical Approval: The study was approved by the IRB in KAIMRC (Ministry of National Guard Health Affairs) for project number RC20-180.
    SAS Institute
    suggested: (Statistical Analysis System, RRID:SCR_008567)
    GraphPad Prism
    suggested: (GraphPad Prism, RRID:SCR_002798)
    GraphPad
    suggested: (GraphPad Prism, RRID:SCR_002798)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    This study has strengths of sampling largely populated, geographically distributed regions; but it has its limitation of using proxy samples and it had a pooling strategy that may not reflect precisely the seroprevalence; therefore, it reports seroprevalence estimation. In conclusion, this study estimates the national serological prevalence of COVID-19 in Saudi Arabia to be 11%, with an apparent disparity between regions. This warrants better vaccination programs and vaccination coverage to increase the immuned population.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.01.28.21250598 on medRxiv